45 results about "Blood coagulation factor XIII" patented technology

The invention provides a preparation method for fibrinogen with the advantages of high dissolution rate in the production process, short production period, fast solubility in clinical use, good biological activity, high safety in clinical use and high yield. An aid is added into supernate anticoagulant plasma. Compared with the prior art, the preparation method has the advantages that: 1, the preparation method provided by the invention is high in extraction efficiency; 2, the aid adopted in the method can improve the quality of the fibrinogen product, and plays a role in protecting the biological activities of the fibrinogen and blood coagulation factors XIII in virus inactivation and cold ethanol settlement processes; 3, in the process, the process solubility time of the fibrinogen is shortened to about 10 minutes; and 4, the solubility time of the freeze dried product of the fibrinogen is within 30 seconds, so precious time is won for rescuing patients in time in clinic.

The present invention relates to prophylactic dosing regimens with long-acting factor IX (FIX) in dosing intervals of 1 week or longer, including (but not limited to) 10 days or longer, such as two weeks, three weeks or even monthly.

A patient having hemophilia A is treated by administering factor XIII generally in conjunction with factor VIII or desmopressin.

Described herein are RPE cells engineered to secrete FVII proteins, as well as compositions, pharmaceutical formulations, and implantable devices comprising these engineered RPE cells, and methods of making and using them for treating patients suffering from hemophilia or FVII deficiency.